They showed that miR-23a released to NK cells as the cargo of hypoxic tumor-derived EVs directly targets LAMP1, leading to a downregulation of its protein product CD107a (a glycosylated lysosomal membrane protein associated with NK cytotoxicity), contributing to the observed immune-suppressive effects of these microvesicles [52]. This evidence concerns the gene LAMP1 and neoplasm.